title: Changes in advanced oxidation protein products, advanced glycation end products, and s-nitrosylated proteins, in patients affected by polycythemia vera and essential thrombocythemia.
abstract: OBJECTIVE
  Oxidative stress has a clear pro tumoral effect in myeloproliferative neoplasms (MPDs). In this study, we analyzed oxidative stress in patients with essential thrombocythemia (ET) and polycythemia vera (PV). Design and methods We analyzed serum levels of advanced oxidation protein products (AOPPs) degradation, advanced glycation end products (AGEs), and protein nitrosylation in ET and PV patients. We also evaluated neutrophil gelatinase-associated lipocalin (NGAL) levels, an acute phase protein isolated in human neutrophils, the activation status of platelets and leukocytes, and the JAK2 (V617F) mutation status.
  
  
  RESULTS
  AOPPs and s-nitrosylated proteins were significantly higher in PV and ET subjects as compared to healthy volunteers, while AGEs were higher in ET subjects with respect to controls. Moreover, in PV patients we found a correlation between s-nitrosylated proteins and Hb value. In ET patients AGEs were significantly higher in patients with thrombosis compared with those without thrombotic events.
  
  
  CONCLUSIONS
  Our results suggest that oxidative stress could play a role in the physiopathology of MPDs and in the onset of myeloproliferative associated thrombotic risk.
authors: Division of Haematology, University of Messina, Messina, Italy.
authors: Caterina
authors: C
authors: Musolino
authors: Alessandro
authors: A
authors: Allegra
authors: Antonella
authors: A
authors: Saija
authors: Andrea
authors: A
authors: Alonci
authors: Sabina
authors: S
authors: Russo
authors: Giovanna
authors: G
authors: Spatari
authors: Giuseppa
authors: G
authors: Penna
authors: Demetrio
authors: D
authors: Gerace
authors: Mariateresa
authors: M
authors: Cristani
authors: Antonio
authors: A
authors: David
authors: Salvatore
authors: S
authors: Saitta
authors: Sebastiano
authors: S
authors: Gangemi
mesh_terms: D000209:Acute-Phase Proteins; D000368:Aged; D001792:Blood Platelets / Q000502:physiology; D001798:Blood Proteins / Q000378:metabolism*; D016022:Case-Control Studies; D005260:Female; D017127:Glycation End Products, Advanced / Q000097:blood*; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics; D000071068:Lipocalin-2; D054834:Lipocalins / Q000097:blood; D008297:Male; D008875:Middle Aged; D020125:Mutation, Missense; D009504:Neutrophils / Q000502:physiology; D009603:Nitroso Compounds / Q000097:blood*; D018384:Oxidative Stress; D015539:Platelet Activation; D011087:Polycythemia Vera / Q000097:blood* / Q000201:enzymology / Q000235:genetics; D011518:Proto-Oncogene Proteins / Q000097:blood; D017422:Sequence Analysis, DNA; D013920:Thrombocythemia, Essential / Q000097:blood* / Q000201:enzymology / Q000235:genetics
chemical_list: D000209:Acute-Phase Proteins; D001798:Blood Proteins; D017127:Glycation End Products, Advanced; C489506:LCN2 protein, human; D000071068:Lipocalin-2; D054834:Lipocalins; D009603:Nitroso Compounds; D011518:Proto-Oncogene Proteins; C507924:JAK2 protein, human; D053614:Janus Kinase 2